• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cystic Fibrosis Foundation opens research lab

Cystic Fibrosis Foundation opens research lab

September 20, 2016
CenterWatch Staff

The Cystic Fibrosis Foundation has announced the official opening of a new, one-of-a kind research facility in Lexington, Massachusetts. Operated by Cystic Fibrosis Foundation Therapeutics (CFFT), an affiliate of the CF Foundation, the lab is designed to identify and test potential therapies for rare and common mutations of cystic fibrosis, with the ultimate goal of bringing new treatments to people living with the disease.

CF is a complex, fatal disease that affects about 30,000 adults and children in the United States and 70,000 people worldwide. It is caused by more than 1,700 genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Although the majority of individuals with CF have at least one copy of the most common mutation, 5% of people carry only nonsense and other types of rare mutations that do not respond to existing drugs—known as CFTR modulators—that treat the underlying cause of the disease.

“Our goal with the new research lab is to speed the development of new treatments for all people with cystic fibrosis,” said William Skach, M.D., senior vice president for research affairs at the CF Foundation. “The lab will provide a unique bridge to fill the gap between academic discovery and the pharmaceutical industry in advancing CF therapies.”

Building on CFFT’s expertise in cell culture, gene editing and stem cell research, the lab’s 25 scientists will spearhead a new initiative to collect and grow cells from people with CF who have nonsense and other rare mutations. These cells will be critical for identifying treatments for rare mutations, and will be made available to academic institutions and pharmaceutical companies to expedite the development of new medications.

The team also will continue to screen promising compounds in order to identify the ones that hold the greatest potential for correcting CFTR mutations.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing